ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
| Revenue (TTM) | $45.49M |
| Gross Profit (TTM) | $27.93M |
| EBITDA | $-29.02M |
| Operating Margin | -52.40% |
| Return on Equity | -167.50% |
| Return on Assets | -21.90% |
| Revenue/Share (TTM) | $1.52 |
| Book Value | $0.85 |
| Price-to-Book | 10.20 |
| Price-to-Sales (TTM) | 6.06 |
| EV/Revenue | 6.72 |
| EV/EBITDA | -7.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.30% |
| Shares Outstanding | $32.05M |
| Float | $26.12M |
| % Insiders | 5.23% |
| % Institutions | 51.43% |
Volatility is currently expanding
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
ClearPoint Neuro NASDAQ: CLPT reported third-quarter 2026 revenue growth of 36% as sales increased across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software businesses. Management said the company is investing in clinical support, laboratory capabilities and product development as it prepares for anticipated cell and gene therapy trial activity and potential commercial launches.
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SOLANA BEACH, CA / ACCESS Newswire / October 14, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 third quarter on Wednesday, October 28, 2026, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 third quarter on Wednesday, October 28 at 4:30 p.m.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES--(BUSINESS WIRE)---- $CLPT--CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLPT and any ticker you trade — then tracks every position and per-strategy win rate.
